CSI Market
Sign In | Register

Keros Therapeutics Inc (KROS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access KROS quarterly Cash Flow →
Tracking cash flow results across Keros Therapeutics Inc to Dec 31 2021 helps illustrate how Dec 31 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income87.01
Depreciation & amortization1.51
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.01
Share-based Compensation28.70
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Operating Lease Right Of Use Asset Amortization Expense2.41
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings-
Increase Decrease In Research And Development Incentive Receivable-
Increase Decrease In Operating Lease Liability-
Right To Use Assets And Operating Lease Liabilities-1.98
Right To Use Assets And Operating Lease Liabilities-1.98
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-3.08
Increase (Decrease) in Accounts Payable-3.00
Increase (Decrease) in Accrued Liabilities-10.13
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets4.02
Other Working Capital2.06
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.98
Discontinued operations0.00
Net Cash flow from Operating Activities107.51
Investing Activities
Capital Expenditures-1.55
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.55
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-374.71
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-561.38
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents561.38
Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Settlement Of Preferred Stock Tranche Obligation-
Payment Of Initial Public Offering Costs-
Preferred Stock Tranche Obligation Issued-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Stock Issuance Costs Incurred But Not Yet Paid-
Conversion Of Stock Amount Converted-
Payment Of Stock Repurchase Costs-3.90
Proceeds From Short Swing Settlement Profit0.14
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-378.47
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow105.95
Total Cash Flow-272.52
4 historic quarters locked

Sign in to unlock the full Keros Therapeutics Inc cash flow history.

Sign In Create Free Account

About Keros Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001664710-26-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License